Optimizing antibiotic treatment for patients with hospital-acquired pneumonia
Development and Evaluation of CRRT-Specific Precision Dosing Models to Optimize Beta-Lactam Treatment for Patients with Hospital-Acquired Pneumonia
This study is looking to make antibiotic treatments better for critically ill patients with hospital-acquired pneumonia caused by tough-to-treat bacteria, by personalizing the doses of medicine they receive to fit their unique needs.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Midwestern University NIH-funded |
| Lab location | 1 site (Downers Grove, United States) |
| Project ID | NIH-10874728 on NIH RePORTER |
What this research studies
This research focuses on improving the treatment of hospital-acquired pneumonia (HAP) caused by antibiotic-resistant bacteria, particularly in critically ill patients undergoing continuous renal replacement therapy (CRRT). The study aims to develop precision dosing models that tailor antibiotic treatment to individual patient needs, addressing the challenges posed by changes in drug metabolism due to critical illness. By leveraging advanced pharmacokinetic and pharmacodynamic principles, the research seeks to enhance the effectiveness of beta-lactam antibiotics like meropenem, which are essential for treating HAP. The goal is to reduce treatment failures and mortality rates in this vulnerable patient population.
Who could benefit from this research
Good fit: Ideal candidates for this research are critically ill patients with hospital-acquired pneumonia who are receiving continuous renal replacement therapy.
Not a fit: Patients who do not have hospital-acquired pneumonia or those not requiring continuous renal replacement therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment outcomes and survival rates for patients suffering from hospital-acquired pneumonia.
How similar studies have performed: Previous research has shown promise in developing precision dosing strategies for other critical care conditions, indicating potential success for this novel approach.
Where this research is happening
Downers Grove, United States
- Midwestern University — Downers Grove, United States (Active)
Researchers
- Principal investigator: Rhodes, Nathaniel James — Midwestern University
- Study coordinator: Rhodes, Nathaniel James
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.